# US 2023/0053708 A1 · Short-chain cpg-containing oligodeoxynucleotide with linked polydeoxyadenylic acid, complex containing said oligodeoxynucleotide, and use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0053708 A1
- Document ID: US20230053708A1
- Status: Published application
- Kind: A1
- Application number: 17/758,036
- Filed: 2020-12-24
- Published: 2023-02-23
- Earliest claimed: 2019-12-25
- Assignees: NapaJen Pharma, Inc.
- Applicants: NapaJen Pharma, Inc.
- Inventors: Kanako AMANO; Atsushi UNO
- Web page: https://patentgrep.com/patent/US20230053708A1

## CPC

- C07H 21/04: with deoxyribosyl as saccharide radical
- A61K 31/7125: Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A61K 31/716: Glucans
- A61K 47/61: the organic macromolecular compound being a polysaccharide or a derivative thereof
- A61P 37/04: Immunostimulants
- C12N 15/117: Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
- C12N 2310/17: Immunomodulatory nucleic acids
- C12N 2310/315: Phosphorothioates
- C12N 2310/3519: Fusion with another nucleic acid
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides an oligodeoxynucleotide which comprises a CpG oligodeoxynucleotide comprising a nucleotide sequence represented by formula (1): 5′X-CpG-L-CpG-TZ3′ (I) wherein X is T or C, L is a nucleotide sequence consisting of 1 to 7 bases, and Z is T or C, and consisting of 8 to 16 bases, and a polydeoxyadenylic acid having a length capable of forming a complex with a β-1,3-glucan, wherein the polydeoxyadenylic acid is linked to the 3′ side of the CpG oligodeoxynucleotide. In addition, the present invention provides a complex containing said oligodeoxynucleotide and a β-1,3-glucan.

## Claims

### Claim 1

An oligodeoxynucleotide which comprises a CpG oligodeoxynucleotide comprising a nucleotide sequence represented by formula (I):
5′X-CpG-L-CpG-TZ3′ (I)
wherein X is T or C,
L is a nucleotide sequence consisting of 1 to 7 bases,
Z is T or C, and
consisting of 8 to 16 bases, and
a polydeoxyadenylic acid having a length capable of forming a complex with a β-1,3-glucan,
wherein the polydeoxyadenylic acid is linked to the 3′ side of the CpG oligodeoxynucleotide.

### Claim 2 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein X is T.

### Claim 3 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein Z is T.

### Claim 4 (depends on 1)

The oligodeoxynucleotide according to claim 1,
wherein L is a nucleotide sequence represented by formula (II):
5′Y1Y2Y3Y4Y5Y6Y73′ (II)
wherein Y1 is a base selected from the group consisting of A, G, T and C, and
Y2, Y3, Y4, Y5, Y6 and Y7 are each independently not present, or are a base selected from the group consisting of A, G, T and C.

### Claim 5 (depends on 4)

The oligodeoxynucleotide according to claim 4, wherein Y3, Y4, Y5, Y6 and Y7 are not present in formula (II).

### Claim 6 (depends on 5)

The oligodeoxynucleotide according to claim 5, wherein Y1 is a base selected from the group consisting of A, G and T.

### Claim 7 (depends on 5)

The oligodeoxynucleotide according to claim 5, wherein Y2 is a base selected from the group consisting of A, G and T.

### Claim 8 (depends on 4)

The oligodeoxynucleotide according to claim 4, wherein Y1 is A or T, Y2 is G or T, Y3 is C or T, Y4 is G or T, Y5 is A or T, Y6 is G or T, Y7 is not present or is A or T.

### Claim 9 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein L is a nucleotide sequence selected from the group consisting of A, G, C, T, AA, AG, AT, GA, GT, TA, TT, TTTTTTT, TTTTTTA, TTCGTTT, TTCGTTA and AGCGAG.

### Claim 10 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the CpG oligodeoxynucleotide has no additional sequence or has an additional sequence of 1 to 3 bases at the 3′ side of the nucleotide sequence represented by formula (I).

### Claim 11 (depends on 10)

The oligodeoxynucleotide according to claim 10, wherein the additional sequence of 1 to 3 bases is a nucleotide sequence selected from the group consisting of C, CT and CTC.

### Claim 12 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the CpG oligodeoxynucleotide has no additional sequence or has one base additional sequence at the 5′ side of the nucleotide sequence represented by formula (I).

### Claim 13 (depends on 12)

The oligodeoxynucleotide according to claim 12, wherein the one base additional sequence is A.

### Claim 14 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the CpG oligodeoxynucleotide consists of 8 to 15 bases.

### Claim 15 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the CpG oligodeoxynucleotide consists of 8 to 12 bases.

### Claim 16 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the nucleotide sequence represented by formula (I) consists of the nucleotide sequence represented by SEQ ID NO: 12, 55, 56, 57, 58, 59, 21, 60, 61, 62, 63 or 64.

### Claim 17 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the nucleotide sequence represented by formula (I) consists of the nucleotide sequence represented by SEQ ID NO: 68, 94, 95, 96, 97, 98 or 99.

### Claim 18 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the CpG oligodeoxynucleotide consists of the nucleotide sequence represented by SEQ ID NO: 4, 6, 7, 8, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 25, 26 or 27.

### Claim 19 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the CpG oligodeoxynucleotide consists of the nucleotide sequence represented by SEQ ID NO: 66, 67, 68, 71, 72, 73, 74, 75, 76 or 77.

### Claim 20 (depends on 1)

The oligodeoxynucleotide according claim 1, wherein some or all of phosphodiester bonds in the oligodeoxynucleotide are replaced by phosphorothioate bonds.

### Claim 21 (depends on 20)

The oligodeoxynucleotide according to claim 20, wherein all of the phosphodiester bonds in the oligodeoxynucleotide are replaced by phosphorothioate bonds.

### Claim 22 (depends on 1)

The oligodeoxynucleotide according to claim 1, wherein the length of the polydeoxyadenylic acid is 20 to 60 bases.

### Claim 23 (depends on 1)

The oligodeoxynucleotide according claim 1, which comprises the nucleotide sequence represented by SEQ ID NO: 31, 33, 34, 35, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 52, 53 or 54.

### Claim 24 (depends on 1)

The oligodeoxynucleotide according to claim 1, which comprises the nucleotide sequence represented by SEQ ID NO: 78, 79, 80, 81, 82, 83, 84, 87, 88, 89, 90, 91, 92 or 93.

### Claim 25 (depends on 1)

A complex which comprises the oligodeoxynucleotide according to claim 1 and a β-1,3-glucan.

### Claim 26 (depends on 25)

The complex according to claim 25, wherein the β-1,3-glucan is schizophyllan.

### Claim 27 (depends on 25)

The complex according to claim 25, wherein the β-1,3-glucan is curdlan.

### Claim 28 (depends on 1)

A pharmaceutical composition which comprises
(i) the oligodeoxynucleotide according to claim 1, and
(ii) a β-1,3-glucan.

### Claim 29 (depends on 28)

The pharmaceutical composition according to claim 28, wherein the oligodeoxynucleotide of (i) forms a complex with the β-1,3-glucan of (ii).

### Claim 30 (depends on 28)

The pharmaceutical composition according to claim 28, wherein the β-1,3-glucan is schizophyllan.

### Claim 31 (depends on 28)

The pharmaceutical composition according to claim 28, wherein the β-1,3-glucan is curdlan.

### Claim at position 32

32-35. (canceled)

### Claim 36 (depends on 25)

A method for enhancing immune response in a mammal, which comprises administering a pharmacologically effective dose of the complex according to claim 25 to the mammal.

### Claim 37 (depends on 25)

A method for inducing production of type I interferon in a mammal, which comprises administering a pharmacologically effective dose of the complex according to claim 25 to the mammal.

### Claim at position 35

38-39. (canceled)
